Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Aviation, Space, and Environmental Medicine|September 6, 2011
Aircrew exposure to handheld laser pointers: the potential for retinal damageStephen Houston
Aerospace Medicine and Human Performance|September 17, 2016
Flying After Conducting an Aircraft Excessive Cabin Leakage TestStephen Houston, Elizabeth Wilkinson
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|April 1, 2011
Prevalence of cardiovascular disease risk factors among UK commercial pilotsStephen Houston, Stuart Mitchell, Sally Evans
Aviation, Space, and Environmental Medicine|August 10, 2012
Fatigue reporting among aircrew: incidence rate and primary causesStephen Houston, Karen Dawson, Sean Butler
Aviation, Space, and Environmental Medicine|August 10, 2012
Commercial air travel after intraocular gas injectionStephen Houston, Jürgen Graf, James Sharkey
Aviation, Space, and Environmental Medicine|August 5, 2010
Application of a cardiovascular disease risk prediction model among commercial pilotsStephen Houston, Stuart Mitchell, Sally Evans
Frontiers in Pediatrics|January 30, 2025
Pedals possible: a pilot study of adaptive cycling as a school-based rehabilitation intervention for students with disabilitiesJulia S Brennan, Everette Keller, Elizabeth Humanitzki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2003
Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancerStephen R D Johnston, Tamas Hickish, Paul Ellis, et al.
Breast Cancer Research and Treatment|March 16, 2012
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumabNancy U Lin, Eric P Winer, Duncan Wheatley, et al.
The Lancet. Oncology|May 16, 2015
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trialHelena M Earl, Louise Hiller, Janet A Dunn, et al.
Pageof 2